Eli Lilly Could Swing Over $76 Billion In Value After Earnings
Earnings season will likely keep the tape jumpy this week, and the options market is already sketching out where the biggest post-print air pockets — and upside gaps — could show up, according to Pro. This is a -selected watchlist that runs from large-cap healthcare to high-beta software and storage names. The marquee name on the list is Eli Lilly, but the largest implied move is saved for the final section as the countdown runs from the least volatile setup to the most. 9. Gilead Sciences | Mkt Cap: $161B | Implied Move: 6.72% Gilead Sciences Inc. (NASDAQ: GILD ) reports second quarter of 2026 results on Tuesday, after the closing bell. Wall Street is looking for a $7.14 per share loss on revenue of $7.40 billion, versus $2.01 in earnings per share on $7.08 billion a year ago — a setup that puts extra weight on the company’s commentary around what’s driving the swing. Pro d...
Earnings season will likely keep the tape jumpy this week, and the options market is already sketching out where the biggest post-print air pockets — and upside gaps — could show up, according to Pro. This is a -selected watchlist that runs from large-cap healthcare to high-beta software and storage names. The marquee name on the list is Eli Lilly, but the largest implied move is saved for the final section as the countdown runs from the least volatile setup to the most. 9.
72% Gilead Sciences Inc. (NASDAQ: GILD ) reports second quarter of 2026 results on Tuesday, after the closing bell. 08 billion a year ago — a setup that puts extra weight on the company’s commentary around what’s driving the swing. 8 billion of market value at stake given Gilead Sciences’ $161 billion market cap.
Gilead Sciences sells therapies for life-threatening infectious diseases, with a core focus on HIV and hepatitis B and C. The stock carries a Buy consensus rating, and the stock is trading below the 180-day average analyst price forecast; in July, Morgan Stanley reiterated its Overweight rating and cut its price forecast, while Leerink Partners downgraded the stock to Market Perform and cut its price forecast. 7% below the 200-day moving average after the 50-day moving average crossed below the 200-day in July. 29.
Read Also: Apple Underestimated Its Own Customers: AAPL CEO Tim Cook Blames 'Demand Forecast Issue' for Q4 Supply Bottlenecks 8. 83% Uber Technologies, Inc. (NYSE: UBER ) reports second quarter of 2026 results on Wednesday, before the opening bell. 65 billion in the prior-year quarter.
With a platform business that can show operating leverage quickly, investors tend to focus on whether growth and profitability are moving in sync. 82 billion of market value at stake for Uber Technologies’ $144 billion market cap. Uber Technologies matches riders with drivers, diners with restaurants and couriers, and shippers with carriers — and that mix can make the quarter’s segment-level momentum and outlook as important as the headline beat or miss.
The stock has a Buy consensus rating, and the share price sits well below the 180-day average analyst price forecast; in July, B of A Securities reiterated its Buy rating and cut its price forecast, while TD Cowen reiterated its Buy rating. 2% below the 200-day moving average. 99. 7.
89% Howmet Aerospace Inc. (NYSE: HWM ) reports second quarter of 2026 results on Thursday, before the opening bell. 05 billion a year ago. For an engineered-solutions supplier tied to aerospace and transportation demand, the quarter often comes down to execution and the durability of end-market strength.
74 billion of market value at stake based on Howmet Aerospace’s $112 billion market cap. Howmet Aerospace makes engineered products for aerospace and transportation customers, and investors will be listening for any read-through on production rates and demand. The stock carries a Buy consensus rating and the 180-day average analyst price forecast is above where the stock trades; in July, RBC Capital, TD Cowen, and Jefferies raised their price forecasts. 1% above the 200-day moving average.
45. 6. Eli Lilly & Co. 37% Eli Lilly & Co.
(NYSE: LLY ) reports second quarter of 2026 results on Wednesday, before the opening bell. 56 billion a year ago. With a large base and big expectations embedded in forecasts, the market’s reaction can hinge on guidance and the cadence of growth more than the quarter’s headline numbers. 37% move.
4 billion of market value at stake. Eli Lilly develops drugs across neuroscience, cardiometabolic, cancer and immunology, keeping the focus on both near-term performance and longer-run pipeline confidence. The stock has a Buy consensus rating and shares trade below the 180-day average analyst price forecast; in July, Citigroup, Bernstein, and UBS raised their price forecasts. 5% above the 200-day moving average.
78. 5. 47% Shopify Inc. (NASDAQ: SHOP ) reports second quarter of 2026 results on Wednesday, before the opening bell.
68 billion a year ago. For a platform tied to small and mid-sized merchants, the quarter can quickly become a referendum on e-commerce demand and take-rate dynamics. 7 billion of market value at stake given Shopify Inc. Class A subordinate voting shares’ $158 billion market cap.
The st